Paulo Belmonte-De-Abreu

Paulo Belmonte-De-Abreu

Auto-generated profile, based on publicly available information

Paulo Belmonte-De-Abreu

Adult ADHD Outpatient Clinic, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2008 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
MKMaurício Kunz
Maurício Kunz
CGClarissa Severino Gama
Clarissa Severino Gama
AAAna Cristina Andreazza
Ana Cristina Andreazza
MSMirian Salvador
Mirian Salvador
KCKeila Mendes Ceresér
Keila Mendes Ceresér
FKFlavio Kapczinski
Flavio Kapczinski

1 June 2007 in Neuroscience Letters
Verified
Journal Article
Closed access
CGClarissa Severino Gama
Clarissa Severino Gama
AAAna Cristina Andreazza
Ana Cristina Andreazza
MKMaurício Kunz
Maurício Kunz
MBMichael Berk
Michael Berk
PBPaulo Silva Belmonte-De-Abreu
Paulo Silva Belmonte-De-Abreu
FKFlavio Kapczinski
Flavio Kapczinski

1 January 2001 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
DLD.R Lara
D.R Lara
CGC.S. Gama
C.S. Gama
PBP. Belmonte-De-Abreu
P. Belmonte-De-Abreu
LPL.V.C. Portela
L.V.C. Portela
CGC.A. Gonçalves
C.A. Gonçalves
DSD.O. Souza
D.O. Souza

1 October 2009 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
BFBrisa Simões Fernandes
Brisa Simões Fernandes
CGClarissa Severino Gama
Clarissa Severino Gama
MKMarcia Kauer-Sant’aNna
Marcia Kauer-Sant’aNna
MLMaria Ines Lobato
Maria Ines Lobato
PBPaulo Belmonte-De-Abreu
Paulo Belmonte-De-Abreu
FKFlavio Kapczinski
Flavio Kapczinski

18 March 2011 in Brazilian Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
MKMauricio Kunz
Mauricio Kunz
KCKeila Maria Ceresér
Keila Maria Ceresér
PGPedro Domingues Goi
Pedro Domingues Goi
GFGabriel Rodrigo Fries
Gabriel Rodrigo Fries
Antonio TeixeiraAntonio Teixeira
Antonio Teixeira
CGClarissa Severino Gama
Clarissa Severino Gama
OBJECTIVE: Previous reports suggest that cytokines act as potential mediators of the interaction between the immune and neuroendocrine systems, and that a proinflammatory state may be associated with bipolar disorder and schizophrenia. The aim is to compare cytokine levels in both disorders. METHOD: Twenty euthymic bipolar disorder patients, 53 chronic stabilized schizophrenia patients and 80 healthy controls were recruited. Subjects were all non-smokers and non-obese. Cytokines TNF-α, IL-6, and IL-10 were examined by sandwich ELISA. RESULTS: IL-6 levels were increased in schizophrenia patients when compared to controls (p < 0.0001) and euthymic bipolar disorder patients (p < 0.0001). IL-6 levels were no different in controls compared to euthymic bipolar disorder patients (p = 0.357). IL-10 was lower in controls compared to schizophrenia patients (p = 0.001) or to bipolar disorder patients (p = 0.004). There was no significant difference in TNF-α serum levels among the groups (p = 0.284). Gender-based classification did not significantly alter these findings, and no correlation was found between the antipsychotic dose administered and cytokine levels in patients with schizophrenia. DISCUSSION: These findings evidence a chronic immune activation in schizophrenia. Bipolar disorder seems to present an episode-related inflammatory syndrome. Increased anti-inflammatory factor IL-10 in bipolar disorder and schizophrenia suggests different patterns of inflammatory balance between these two disorders. Results further support the need to investigate cytokines as possible biomarkers of disease activity or treatment response.

15 October 2009 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
DLDavid de Lucena
David de Lucena
BFBrisa Simões Fernandes
Brisa Simões Fernandes
MBMichael Berk
Michael Berk
SDSeetal Dodd
Seetal Dodd
DMDalton W. Medeiros
Dalton W. Medeiros
CGClarissa Severino Gama
Clarissa Severino Gama
Glutamate deregulation may be involved in the neuropathology of schizophrenia, mainly through N-methyl-d-aspartate (NMDA) receptor dysfunction. Memantine, a drug approved by the FDA for the treatment of moderate to severe Alzheimer's disease, acts as a weak nonselective NMDA receptor antagonist. The aim of this study was to examine the efficacy of memantine as an adjunctive treatment to clozapine in patients with refractory schizophrenia. In this double-blind, placebo-controlled study, outpatients with refractory schizophrenia according to DSM-IV clinical criteria were randomly assigned, from March 2005 to February 2008, to receive either 20 mg/d memantine (n = 10) or placebo (n = 11), in addition to clozapine, for 12 weeks. The primary outcome measure was the total score on the 18-item Brief Psychiatry Rating Scale (BPRS) and BPRS subscales of positive and negative symptoms. Secondary outcomes were global severity of disease as measured by the Clinical Global Impressions scale (CGI), cognition as assessed by the Mini-Mental State Examination (MMSE), and extrapyramidal symptoms as assessed by the Simpson-Angus Scale (SAS). Twenty-one participants completed the study and were used in the analysis. Significant improvement (P < .01) on the total BPRS score, its subscales of positive (effect size [ES] = -1.38) and negative (ES = -3.33) symptoms, the CGI score (ES = 1.56), and the MMSE score was observed with memantine as compared with placebo. No significant changes in extrapyramidal symptoms were observed. Memantine add-on to clozapine therapy was associated with improvement in negative and positive symptoms in refractory schizophrenia patients. clinicaltrials.gov Identifier: NCT00757978.